Abstract:We read with interest the case report by Zander et al. describing a patient with thymoma that was responsive to low-dose pembrolizumab.1Zander T. Aebi S. Rast A.C. et al.Response to pembrolizumab in a patient with relapsing thymoma.J Thorac Oncol. 2016; 11: e147-e149Abstract Full Text Full Text PDF PubMed Scopus (28) Google Scholar High rates of programmed cell death 1 ligand 1 (PD-L1) expression have been found in thymic epithelial tumors and are associated with more aggressive types and advanced stages at diagnosis.2Katsuya Y. Fujita Y. Horinouchi H. Ohe Y. Watanabe S. Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.Lung Cancer. 2015; 88: 154-159Abstract Full Text Full Text PDF PubMed Scopus (124) Google Scholar However, the efficacy of programmed cell death 1 (PD-1)/PD-L1 blockade for thymoma or thymic carcinoma has not yet been investigated in large-scale clinical trials. Another case demonstrating response to pembrolizumab in a patient with thymic epithelial tumor has been published.3Yang Y. Ding L. Wang P. Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.J Thorac Dis. 2016; 8: E535-E537Crossref PubMed Scopus (14) Google Scholar We present a case of thymic carcinoma with partial response to nivolumab. Thymic carcinoma with squamous cell differentiation was diagnosed in a 62-year-old woman (Fig. 1). Her disease was staged cT4N3M1 at diagnosis, with metastases in the mediastinal, bilateral hilar, and supraclavicular lymph nodes, as well as in the lung, pleura, and pericardium. Chemotherapy with paclitaxel and cisplatin (cisplatin, 70 mg/m2 once on day 1, and paclitaxel, 60 mg/m2 once on days 1 and 8, repeated every 21 days) led to a partial response. However, progression of the primary mediastinal tumor, pleural seeding, new right hilar lymphadenopathy, and a new liver metastasis were found by computed tomography (CT) scan after a total of eight cycles of paclitaxel and cisplatin. Four cycles of doxorubicin and cyclophosphamide (doxorubicin, 50 mg/m2, and cyclophosphamide, 500 mg/m2, once every 3 weeks) thereafter resulted in stable disease in the mediastinal mass, hilar nodes, and pleural seeding but enlarged liver metastasis. The patient then received three cycles of biweekly gemcitabine and infusional 5-fluorouracil and leucovorin (gemcitabine, 1000 mg/m2, and 5-fluorouracil, 2400 mg/m2, plus leucovorin, 300 mg/m2, in a 48-hour infusion). However, intermittent hemoptysis developed and was followed by an episode with dyspnea and impaired gas exchange. The subsequent CT scan showed progression of the mediastinal mass, liver metastasis, and right hilar lymphadenopathy, with suspected invasion of the right bronchus (Fig. 2A and 2C). Palliative radiotherapy (33 Gy in 10 fractions) to the thymic tumor and right hilar lymphadenopathy for symptomatic and potentially life-threatening tumor bleeding was performed. The patient also received nivolumab (2 mg/kg repeated every 3 weeks), and the hemoptysis subsided thereafter. A CT scan after the fourth cycle of nivolumab showed a partial response, including the liver metastasis, which was not within the radiation field (Fig. 2). The patient experienced only grade 1 skin rash, which was controlled by topical agents. Biomarkers predictive of response to nivolumab were tested by immunohistochemical staining, which disclosed 1% (composed of tumor cells and immune cells) PD-L1 expression (SP142) (Fig. 3) and proficient mismatch repair with a preserved mutS homolog 6, PMS1 homolog 2, mismatch repair system component, and mutL homolog 1 expression (see Fig. 3). Our case suggests that nivolumab may also be an efficacious and safe option in the treatment of metastatic thymic carcinoma. Currently, two phase II trials examining the efficacy of pembrolizumab in thymic epithelial tumors are ongoing, with response rates of approximately 24%.4Giaccone G. Thompson J. McGuire C. et al.Pembrolizumab in patients with recurrent thymic carcinoma: results of a phase II study.J Clin Oncol. 2017; 35 ([abstract]): 8573Google Scholar, 5Cho J. Ahn M.J. Yoo K.H. et al.A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.J Clin Oncol. 2017; 35 ([abstract]): 8521Google Scholar High rates of immune-related adverse events were also reported by Cho et al.5Cho J. Ahn M.J. Yoo K.H. et al.A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.J Clin Oncol. 2017; 35 ([abstract]): 8521Google Scholar A phase II trial studying nivolumab in patients with World Health Organization (WHO) type B3 and C thymomas (NIVOTHYM, NCT03134118) is expected to start accrual in 2018. We thank the patient for consenting to this publication.

Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report

Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature

Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience

Primary pulmonary lymphoepithelioma-like carcinoma: a rare type of lung cancer with a favorable outcome in comparison to squamous carcinoma

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma

Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients

Neoadjuvant immunotherapy in patients with pulmonary lymphoepithelioma-like carcinoma

Response to Nivolumab As Salvage Therapy in a Patient with Thymic Carcinoma

Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification

Surgical Treatment of Epstein-Barr Virus–associated Lymphoepithelioma-Like Carcinoma Occurring in Both the Posterior Mediastinum and Liver

Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival

Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome

Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease

Primary lymphoepithelioma-like carcinoma of the lung: distinct computed tomography features and associated clinical outcomes

Nivolumab Treatment of Relapsed/refractory Epstein-Barr Virus–associated Hemophagocytic Lymphohistiocytosis in Adults

First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma

Clinical observation of pulmonary lymphoepithelioma-like carcinoma

Lymphoepithelioma-like carcinoma of the lung: experience with ten cases

[Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients]

Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review

Multimodality treatment and long-term follow-up of the primary pulmonary lymphoepithelioma-like carcinoma